CD31-Derived Peptide Binding CD38 Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The physiological role of CD38 receptor activation by CD31 remains elusive, and existing methods primarily rely on agonistic anti-CD38 antibodies, limiting therapeutic options for diseases involving CD38 and CD31 interactions.
Innovation Solution
A minimal 5-amino acid peptide derived from human CD31 specifically binds to CD38, activating the CD38 receptor function, offering a new therapeutic approach for inflammatory, autoimmune, metabolic, and neuroinflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If agonistic anti-CD38 antibodies are used to activate CD38 receptor function, then therapeutic effect is achieved, but device complexity and manufacturing cost increase
Solution Approach 1:
The patent extracts the essential binding function from the full-length CD31 protein by identifying and isolating a minimal 5-amino acid peptide sequence (NFVIL) that retains the ability to specifically bind and activate CD38. This extraction principle resolves the contradiction by providing a simplified therapeutic agent that maintains efficacy while reducing complexity compared to full antibody therapies.
Solution Approach 2:
The patent creates a simplified copy of the natural CD31-CD38 interaction by synthesizing a peptide that replicates the key binding interface. Instead of using complex natural antibodies or full-length CD31, the invention copies only the essential 5-amino acid motif required for CD38 activation, thereby achieving therapeutic effect with reduced molecular complexity.
2Reliability
If full-length CD31 or large protein fragments are used to activate CD38, then receptor function is activated, but ease of manufacture and delivery decrease
Solution Approach 1:
The patent segments the large CD31 protein into its functional components by identifying the minimal 5-amino acid peptide (NFVIL) that contains the CD38-binding activity. This segmentation allows the therapeutic agent to be manufactured as a simple peptide rather than a complex protein, dramatically improving ease of manufacture and delivery while maintaining receptor activation capability.
Solution Approach 2:
The patent employs a short peptide sequence instead of a large protein, creating a simpler, more economical therapeutic agent. The 5-amino acid peptide is far easier and cheaper to manufacture than full-length CD31 or antibody therapies, and can be produced through simple chemical synthesis rather than complex protein expression systems.
3Ease of manufacture
If peptide length is reduced to minimal sequence, then ease of manufacture increases, but binding specificity and affinity may decrease
Solution Approach 1:
The patent identifies and copies the precise 5-amino acid sequence (NFVIL) from the natural CD31 protein that forms the critical binding interface with CD38. By copying only this essential motif, the peptide maintains high binding specificity and affinity for CD38 despite its minimal length, resolving the contradiction between simplicity and effectiveness.
Solution Approach 2:
The patent optimizes the peptide sequence by identifying the specific 5-amino acid motif (NFVIL) that provides optimal binding characteristics. Through sequence analysis and validation, the invention determines that this specific parameter combination (5 amino acids with this particular sequence) achieves the right balance between manufacturing simplicity and binding specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD31 peptide demonstrates neuroprotective and anti-inflammatory effects, providing a promising treatment for various diseases by specifically interacting with CD38, potentially replacing traditional antibody-based therapies.
Implementation Method 1
A minimal 5-amino acid peptide derived from human CD31 specifically binds to CD38, activating the CD38 receptor function
Data Source
AI summary
Peptides derived from CD31, specifically binding to CD38. Also, the use of these peptides in prevention and/or treatment of diseases, including diseases characterized by increased levels of soluble CD38 in a subject and/or a reduced soluble CD31 level/soluble CD38 level ratio, and reducing the severity of fibrosis and/or slowing down the progression of fibrosis and/or preventing the development of fibrosis in a subject. Further, methods of increasing the level of at least one anti-inflammatory cytokine in a subject, lowering glucose levels in a subject, and promoting or enhancing reparation of DNA lesions induced by a chemotherapeutic agent in a subject.